Topical SGX302 for Mild-to-Moderate Psoriasis

Phase

Condition

Rash

Warts

Skin Wounds

Treatment

Placebo

Hypericin

Clinical Study ID

NCT05442190

HPN-PSR-01

Ages 18-75
All Genders

Study Summary

To evaluate SGX302 (topical hypericin ointment and gel) with visible light in an initial 18-week treatment course for improving lesions in patients with mild-to-moderate psoriasis.

Eligibility Criteria

Inclusion

Inclusion Criteria:

Have a clinical diagnosis of plaque psoriasis (psoriasis vulgaris) of at least 6-months duration that involves the body (trunk and/or limbs) that is amenable totopical treatment and opaque coverage after application.
Have a static Investigator Global Assessment (IGA)/Psoriasis Area and Severity Index (PASI) of disease severity of mild or moderate on the body (trunk and/or limbs).
Have lesions involving 2-30% of the body (trunk and/or limbs). For subjects withscalp psoriasis included in the treatment area, the total treatment area on body andscalp must not exceed 30%.

Exclusion

Exclusion Criteria:

Use of topical anti psoriatic therapy within one week prior to the beginning of thestudy and willing to not use other psoriasis treatments for 4 weeks followingcompletion of the treatment portion of the study.
Received systemic biologic therapy to treat psoriasis within 12 weeks prior to thebeginning of the study.
Received systemic psoriasis therapy within 4 weeks prior to the beginning of thestudy.
Received phototherapy (including laser) or photodynamic (light activated drug)therapy within 4 weeks prior to the beginning of the study.

Study Design